Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,878 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High dose of ascorbic acid induces cell death in mesothelioma cells.
Takemura Y, Satoh M, Satoh K, Hamada H, Sekido Y, Kubota S. Takemura Y, et al. Among authors: hamada h. Biochem Biophys Res Commun. 2010 Apr 2;394(2):249-53. doi: 10.1016/j.bbrc.2010.02.012. Epub 2010 Feb 19. Biochem Biophys Res Commun. 2010. PMID: 20171954
Aminopeptidase N/CD13 as a potential therapeutic target in malignant pleural mesothelioma.
Otsuki T, Nakashima T, Hamada H, Takayama Y, Akita S, Masuda T, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Miyata Y, Miyake M, Kohno N, Okada M, Hattori N. Otsuki T, et al. Among authors: hamada h. Eur Respir J. 2018 May 24;51(5):1701610. doi: 10.1183/13993003.01610-2017. Print 2018 May. Eur Respir J. 2018. PMID: 29519924 Free article.
Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study.
Yamaguchi K, Masuda T, Fujitaka K, Miwata K, Sakamoto S, Horimasu Y, Hamai K, Miyamoto S, Nakashima T, Okamoto Y, Iwamoto H, Ishikawa N, Miyata Y, Okada M, Hamada H, Hattori N. Yamaguchi K, et al. Among authors: hamada h. In Vivo. 2018 Sep-Oct;32(5):1155-1160. doi: 10.21873/invivo.11358. In Vivo. 2018. PMID: 30150438 Free PMC article. Clinical Trial.
Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts.
Masuda T, Nakashima T, Namba M, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Miyata Y, Hamada H, Okada M, Hattori N. Masuda T, et al. Among authors: hamada h. J Cell Mol Med. 2019 Apr;23(4):2984-2994. doi: 10.1111/jcmm.14205. Epub 2019 Feb 7. J Cell Mol Med. 2019. PMID: 30734495 Free PMC article.
Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.
Nakanishi Y, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Tsutani Y, Iwamoto H, Fujitaka K, Miyata Y, Hamada H, Okada M, Hattori N. Nakanishi Y, et al. Among authors: hamada h. Respir Investig. 2019 Sep;57(5):451-459. doi: 10.1016/j.resinv.2019.05.002. Epub 2019 Jun 24. Respir Investig. 2019. PMID: 31248832
Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer.
Nakanishi Y, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Mimae T, Nakashima T, Miyamoto S, Tsutani Y, Iwamoto H, Fujitaka K, Miyata Y, Hamada H, Okada M, Hattori N. Nakanishi Y, et al. Among authors: hamada h. Int J Clin Oncol. 2020 Jan;25(1):74-81. doi: 10.1007/s10147-019-01539-2. Epub 2019 Sep 17. Int J Clin Oncol. 2020. PMID: 31531785
1,878 results